Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.39 Million CNY | 8.95% |
| 2022 | 3.11 Million CNY | -25.99% |
| 2021 | 4.21 Million CNY | 52.21% |
| 2020 | 2.76 Million CNY | 2.33% |
| 2019 | 2.7 Million CNY | 18.35% |
| 2018 | 2.28 Million CNY | 17.43% |
| 2017 | 1.94 Million CNY | -19.23% |
| 2016 | 2.4 Million CNY | 1.13% |
| 2015 | 2.38 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 3 Million CNY | -11.4% |
| 2024 Q2 | 3 Million CNY | 0.0% |
| 2023 Q4 | 3.39 Million CNY | 0.0% |
| 2023 Q2 | 3.44 Million CNY | 0.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 FY | 3.39 Million CNY | 8.95% |
| 2022 Q1 | - CNY | -100.0% |
| 2022 FY | 3.11 Million CNY | -25.99% |
| 2022 Q4 | 3.11 Million CNY | 0.0% |
| 2022 Q3 | - CNY | -100.0% |
| 2022 Q2 | 3.28 Million CNY | 0.0% |
| 2021 Q2 | 3.88 Million CNY | 0.0% |
| 2021 Q1 | - CNY | -100.0% |
| 2021 FY | 4.21 Million CNY | 52.21% |
| 2021 Q4 | 4.21 Million CNY | 0.0% |
| 2020 Q4 | 2.76 Million CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 2.76 Million CNY | 2.33% |
| 2020 Q2 | 3.9 Million CNY | 0.0% |
| 2019 Q2 | 3.27 Million CNY | 0.0% |
| 2019 Q4 | 2.7 Million CNY | 0.0% |
| 2019 FY | 2.7 Million CNY | 18.35% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 FY | 2.28 Million CNY | 17.43% |
| 2018 Q4 | 2.28 Million CNY | 0.0% |
| 2018 Q2 | 1.85 Million CNY | 0.0% |
| 2017 FY | 1.94 Million CNY | -19.23% |
| 2016 FY | 2.4 Million CNY | 1.13% |
| 2015 FY | 2.38 Million CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 12.19 Million HKD | 72.165% |
| Grand Pharmaceutical Group Limited | 1.38 Billion HKD | 99.756% |
| Extrawell Pharmaceutical Holdings Limited | 7.26 Million HKD | 53.269% |
| Wai Yuen Tong Medicine Holdings Limited | 308.09 Million HKD | 98.898% |
| Qianhai Health Holdings Limited | 431.78 Million HKD | 99.214% |
| Lee's Pharmaceutical Holdings Limited | 298.1 Million HKD | 98.861% |
| Essex Bio-Technology Limited | 62.82 Million HKD | 94.596% |
| Tongfang Kontafarma Holdings Limited | 98.26 Million HKD | 96.545% |
| PuraPharm Corporation Limited | 175.59 Million HKD | 98.067% |
| SSY Group Limited | 1.08 Billion HKD | 99.687% |
| JBM (Healthcare) Limited | 91.58 Million HKD | 96.293% |
| Jacobson Pharma Corporation Limited | 317.85 Million HKD | 98.932% |
| China Resources Pharmaceutical Group Limited | 35.09 Billion HKD | 99.99% |